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Short Communication
Low dose irradiation permits immunization ofA/J mice with
subimmunogenic numbers of Sal cells
R.E. Anderson, S. Tokuda, W.L. Williams & C.W. Spellman
University ofNew Mexico, School ofMedicine, Albuquerque, NM 87131, USA.
In general, antigen injection is followed by an
immune response characterized by the interaction
of several cell types (Cantor & Gershon, 1979;
Gershon, 1980). However, small amounts of some
antigens are associated with either the absence of a
detectable response or elimination of the responsive
clone (Nossal et al., 1976). The induction of
suppressor thymus derived lymphocytes (T cells)
has been evoked to explain the development of low
zone tolerance, a mechanism which may also be
involved in the apparent absence of an immune
response among animals possessing a tumour of
known antigenicity (Schatten et al., 1984). In a
series of experiments designed to examine the inter-
relationships between irradiation and tumour
immunity, we noted that low dose irradiation
permitted immunization of A/Jax (A/J) mice with
numbers of Sarcoma I (Sal) cells that otherwise
elicited either partial tolerance or no detectable
immune response.
Six week old female mice of the A/J strain were
purchased from the Jackson Laboratory (Bar
Harbor, Maine) and permitted to acclimatize prior
to use.
The Sal tumour used in this study represents a
methylcholanthrene-induced fibrosarcoma which is
syngeneic to A/J (H -2a) mice. The induction ofcell-
mediated immunity to this tumour has been
described elsewhere (Anderson et al., 1982; Schatten
et al., 1984). It was obtained locally from the
Jackson Laboratory in 1974 as a solid tumour,
converted to the ascitic form, passaged and stored
in liquid nitrogen. When needed, frozen aliquots
were thawed, injected i.p. and then transferred in
serial fashion in 8-12 week male A/J mice. The
ascitic tumour cells used in the present studies were
derived from the 5th-14th transplant generation
and harvested one week after injection. Differences
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in tumour growth were apparent between the
extremes of the transplant generation. For
immunization purposes, freshly harvested ascitic
cells were inactivated in one of three ways as
follows: 1) 107 SaI cells were treated with lOO1 g
mitomycin in 1 ml of RPMI-1640 for 30min at
37°C; 2) 106 SaI cells were treated with 1 ml of 1%
paraformaldehyde in 0.85% NaCl for 30min at
4°C; 3) 107 SaI cells in 1 ml of RPMI-1640 were
irradiated with 50Gy at a dose rate of
2.6Gymin-1 in a G.E. Maximar 250 III X-ray
machine. The cells were then washed and
resuspended in PBS, and 0.2ml containing the
indicated number of cells was injected s.c. into the
left flank. To assess immunity, 104 washed SaI cells
(>95% viable) in 0.2ml PBS were injected s.c. into
the left flank 21 days later. The site of injection of
these cells was then palpated daily by a single
observer without knowledge of prior treatments of
the mice. When tumours developed, they were
carefully measured on alternate days with vernier
calipers. The tumour area was calculated by
multiplying the largest dimension by its
perpendicular diameter. Mice were irradiated in
whole body fashion as described elsewhere
(Anderson et al., 1982).
Flow analysis of lymphocytes was performed on
a fluorescent-activated cell sorter (FACS III,
Becton Dickinson, Mountain View, CA) as
described elsewhere (Lanier et al., 1981). Routinely,
1 x 104 viable cells were analyzed per data point.
The proportions of T cell subsets were determined
by comparing: (a) the percent of cells staining
positively with the monoclonal anti-Lyt-1, clone 53-
7.313 (which stains Lyt-1+2- and Lyt-1+2+ cells)
or the monoclonal anti-Lyt-2, clone 53-6.93 (which
stains Lyt-1 -2 and Lyt-1 +2 cells) with (b) the
total numbers of Thy-1.2 cells (clone 30-H-12,
monoclonal antibody anti-Thy-1.2). A fluorescent
mouse anti-rat Ig monoclonal antibody (clone
MAR 18.5) was used as the second step reagent.
Monoclonal antibodies were obtained from Becton
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Dickinson. The percent of individual cell types was
determined by a subtractive procedure. For
example, %Lyt-2=(%Ominus %Lyt-1). The results
are comparable with two colour analysis.
Unless specified, each experimental group
contained 20 mice and the results expressed as the
mean of the individual determinations. Statistical
comparisons between tumour growth curves were
made on log transformed data (Sokal & Rohlf,
1969).
Figure 1 shows the effect of whole body exposure
to 0.15Gy upon the response of A/J mice to
mitomycin-treated Sal cells. The mice were
irradiated or sham irradiated immediately prior to
injection with varying numbers of mitomycin-
treated tumour cells. A control group was injected
with PBS. Twenty-one days later, all animals
received 104 viable Sal cells. As seen in the Figure,
sham irradiated mice injected with 102 mitomycin-
treated SaI cells exhibit larger tumours than the
PBS injected controls (solid line) when subsequently
challenged with untreated tumour cells. Exposure to
0.15Gy not only abolishes this partial tolerance to
Sal, but actually renders the irradiated mice
partially immune. Injection with 103-105 treated
tumour cells results in variable degrees of immunity
in both the sham irradiated and the 0.15Gy groups.
However, the level of immunity is almost always
greater in the irradiated mice.
Figure 2 summarizes the results of three
experiments similar to those shown in Figure 1. In
this group of experiments, injection with 102
mitomycin-treated Sal cells had little apparent
influence upon the sham irradiated mice. However,
exposure to 0.15Gy is associated with a highly
significant (P<0.001) reduction in tumour size.
With larger numbers of treated tumour cells,
variable degrees of immunity are seen in both
groups but are uniformly greater in 0.15Gy
animals. Immunization with an unrelated tumour
(MOPC-l1) had no effect on the subsequent growth
of 104 SaI cells with or without 0.15Gy (data not
shown).
Figure 3 shows an experiment similar to that
described in Figures 1 and 2 except that the Sal
cells utilized for injection were inactivated by
exposure to 50Gy. Exposure to 0.15Gy under these
circumstances is not associated with a heightened
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Figure 1 Effect of 0.15 Gy upon response of A/J mice to varying numbers ofmitomycin-treated SaI cells.*
*Groups of 20 mice were exposed to 0.15Gy whole body irradiation or sham irradiated, and inoculated s.c.
with the indicated numbers of mitomycin-treated tumour cells. Twenty-one days later, all animals received 104
untreated SaI cells and were followed for tumour size. A control group (solid line) did not receive mitomycin-
treated cells.
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Figure 2 Effects of 0.15 Gy upon response of A/J mice to mitomycin-SaI cells.*
*Experimental approach similar to that described in legend for Figure 1, except that each group contained 60
mice.
level of immunity. Inactivation of the Sal cells with
formalin generally yields results comparable to
those found with mitomycin treatment (data not
shown).
Table I summarizes an experiment designed to
look at the effect of 0.15Gy upon T cell subsets in
mice immunized with small numbers of Sal cells.
On day 0, mice were exposed to 0.15Gy or sham
irradiated and then injected with 150 SaI cells. A
control group was injected with PBS. On day 5,
mice from each group were sacrificed for an
assessment of lymphocyte subsets. With respect to
the relative proportion of T cell subsets in lymph
node, injection of mitomycin-treated Sal cells
(Group II) is associated with a marked decrement
in the Lyt-1 +2+ phenotype with corresponding
increments in the other two T cell subsets,
particularly the Lyt-1-2+ phenotype. Irradiation
administered prior to immunization appears to
mute this shift, especially with respect to the Lyt-
1-2+ phenotype. Corresponding observations with
spleen cells show no consistent differences among
the groups.
The basis for the progressive growth of tumours
known to be antigenic to the autochthonous host is
not well understood. A variety of mechanisms have
been proposed to explain this apparent paradox
including antigenic modulation (Stackpole &
Jacobson, 1978) and blocking factors (Hellstrom &
Hellstrom, 1977). Recently, suppressor T cells have
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Figure 3 Effects of 0.15 Gy upon response of A/J mice to lethally irradiated Sal cells.*
*Experimental approach similar to that described in legend for Figure 1 except that tumour cells were
inactivated by exposure to 50Gy.
Table I Distribution by Lyt phenotype of splenic and lymph node T cells in mice exposed to 0.15Gy and
injected with subimmunogenic numbers ofmitomycin-treated Sal cellsa
T cell subsets
Radiation No. mitomycin- Tissue
Group dose treated SaI cells assessed Lyt-1+2+ Lyt-1+2- Lyt-1-2+ Other
I OGy Spleen 12 21 4 63
Lymph node 21 39 6 34
II OGy 150 Spleen 12 22 2 64
Lymph node 0 48 18 34
III 0.15Gy 150 Spleen 5 26 10 59
Lymph node 8 49 7 36
aGroups of 30 mice were exposed to 0.15Gy or sham irradiated and then immunized with 150
mitomycin-treated Sal cells. A control group was injected with PBS. On day 5 after irradiation and
injection, 5 mice from each group were sacrificed for a determination of T cell subsets in spleen and lymph
node. The remainder of the mice were injected with 104 Sal cells on day 21 and followed for tumour size.IRRADIATION PERMITS TUMOUR CELL IMMUNIZATION 509
also been implicated (Schatten et al., 1984;
Spellman & Roberts, 1983; Carter et al., 1983).
Whatever the mechanism, however, the end result is
that the host appears to be tolerant, or partially
tolerant, to the tumour.
Whole body irradiation has been employed both
to terminate and to generate tolerance. The
involved doses, however, have been in the low to
mid-lethal dose range (Nossal & Larkin, 1959;
Anderson & Warner, 1976) and thus considerably
greater than those employed herein.
In the present series of experiments, whole body
exposure to 0.15Gy prior to immunization results
in partial immunity in both the 'tolerant' and the
'nonimmune' groups. This observation suggests that
the absence of a demonstrable anti-tumour response
in the sham irradiated animals exposed to 102
mitomycin-treated cells (Figure 2) does not indicate
that the number of cells is below the threshold
required to initiate a response. Rather, it implies
that 102 SaI cells trigger a balanced state of
immunity between the effector and suppressor
components. The consequence is no observable
deviation from the control situation. Low dose
irradiation, which inhibits the tumour-associated
shifts in T cell subsets, appears to perturb this
balance and permits the anti-tumour effector
component to predominate. A somewhat analogous
situation has been reported in rats (Baldwin et al.,
1982) and mice (Perry & Greene, 1982) treated with
low dose cyclophosphamide prior to treatment with
a KC1 extraction of rat hepatoma or heavily
irradiated S1509 plus anti-I-Ak alloantiserum
respectively; these two priming regions were
ineffective in the absence of cyclophosphamide.
Preliminary experiments suggest that low doses of
cyclophosphamide and radiation, used conjointly,
are more effective in permitting immunization with
small numbers of mitomycin-treated Sal cells than
in either agent employed alone. Spleen cells from
mice immunized in this fashion can be employed to
adoptively transfer partial immunity to adult
thymectomized-lethally irradiated-bone marrow
restored recipients.
Inactivation of tumour cells with formalin but
not lethal (50Gy) irradiation yields results
comparable to those with mitomycin. The basis of
this difference among inactivating agents is not
known but may relate to the marked alterations
caused by irradiation to the surface topography of
susceptible cells (Anderson & Warner, 1976).
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